Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Deciphering the role of RET in cancer and breakthroughs in targeted treatments

Xueqing Hu , Ujjwol Khatri , Tao Shen , and Jie Wu, at University of Oklahoma Health Sciences Center, USA, provides a comprehensive review of the role of the RET (REarranged during Transfection) receptor tyrosine kinase in cancer development and the advancements in RET-targeted cancer therapies.

19 Jul 2024

RNA splicing modulation as a precision approach for neuroendocrine cancer treatment

Neuroendocrine tumors, including small cell lung cancer and neuroendocrine prostate cancer, are very aggressive with high chances of spreading.

2 Jul 2024

Pristimerin induces apoptosis in non-small cell lung cancer by targeting thioredoxin reductase

Announcing a new publication for Acta Materia Medica journal. Elevated cellular oxidative stress is a common marker of cancer cell dysregulation caused by malignant transformation.

30 Jun 2024

JAK1 inhibition and Anti-PD1 therapy enhance outcomes in advanced lung cancer

Adding an anti-inflammatory drug to anti-PD1 checkpoint inhibitor immunotherapy has shown great promise as a new strategy against advanced lung cancer, based on results from a small clinical trial led by investigators at the Abramson Family Cancer Center at the University of Pennsylvania Perelman School of Medicine.

21 Jun 2024

Combination therapy shows great promise as a new strategy against advanced lung cancer

21 Jun 2024

Evaluation of serum tumor markers as adjuncts in NSCLC management

A new research paper was published in Oncotarget's Volume 15 on June 13, 2024, entitled, "Assessment of serum tumor markers CEA, CA-125, and CA19-9 as adjuncts in non-small cell lung cancer management."

20 Jun 2024

Combining JAK inhibitors with checkpoint inhibitors improves cancer immunotherapy response

Because not all cancer patients respond to a leading type of cancer immunotherapy drug, known as an immune checkpoint inhibitor, scientists explored whether adding janus kinase (JAK) inhibitors – drugs that treat chronic inflammation – could help.

20 Jun 2024

Study reveals why EGFR inhibitors fail in some non-smokers with lung cancer

The reason why targeted treatment for non-small cell lung cancer fails to work for some patients, particularly those who have never smoked, has been discovered by researchers from UCL, the Francis Crick Institute and AstraZeneca.

13 Jun 2024

Study uncovers why targeted therapy fails in some non-small cell lung cancer patients

13 Jun 2024

Episodic hypoxemia from sleep apnea tied to increased lung cancer relapse

A new study to be presented at the SLEEP 2024 annual meeting is the first to find that episodic hypoxemia and hypoxic burden related to obstructive sleep apnea are associated with the risk of accelerated lung cancer reoccurrence.

4 Jun 2024

Novel combination treatment outperforms standard therapy in patients with EGFR NSCLC

The combination of the antibody amivantamab and lazertinib, a drug targeting EGFR, shows better clinical benefits compared to standard treatment in patients with advanced or metastatic non-small cell lung cancer with EGFR gene mutations who also present one of these poor prognosti markers: brain and/or liver metastases, p53 gene co-mutations, or the presence of circulating tumor DNA.

4 Jun 2024

Study reveals disparities in the delivery of cancer-related care at minority serving hospitals

It’s important to ensure that care provided at US hospitals that predominantly serve Black and Hispanic populations is as high-quality as the care provided at other US hospitals. New research reveals significant disparities in the delivery of cancer-related care at minority serving hospitals (MSHs) compared with non-MSHs, however.

3 Jun 2024

Study examines the cost-effectiveness of a targeted immunotherapy for lung cancer

Many countries with national healthcare systems or payers such as insurance companies use cost-effectiveness analyses to decide whether to cover new medicines, balancing treatment costs with potential health benefits.

30 May 2024

Targeting CD47 to improve osimertinib efficacy in EGFR mutant NSCLC

NSCLC is the leading cause of cancer deaths globally, with EGFR mutations being a common feature in these cancers.

28 May 2024

Study reveals cancer treatment disparities at minority-serving hospitals

It’s important to ensure that care provided at US hospitals that predominantly serve Black and Hispanic populations is as high-quality as the care provided at other US hospitals.

27 May 2024

AI-based body composition analysis predicts lung cancer treatment outcomes

Tafadzwa Chaunzwa, MD, a researcher in the Artificial Intelligence in Medicine (AIM) Program at Mass General Brigham and a senior resident physician at the Harvard Radiation Oncology Program, is the lead author of a paper published in JAMA Oncology.

24 May 2024

New AI model sets benchmark in digital pathology with superior cancer diagnostics

Researchers developed Prov-GigaPath, a whole-slide pathology foundation model using a novel vision transformer architecture. The model demonstrates superior performance in mutation prediction, cancer subtyping, and vision-language tasks. It leverages large-scale real-world data from over 30,000 patients to enhance clinical diagnostics.

23 May 2024

Low-fat diets significantly reduce lung cancer risk in older adults, study finds

Study found that adhering to low-fat diets significantly reduces lung cancer risk in older adults, with the most substantial benefits observed in current smokers. High consumption of saturated fats was linked to increased lung cancer risk, particularly for small-cell lung cancer.

20 May 2024

New PET imaging biomarker Gal-1 predicts tumor responses to immunotherapy

The protein galectin-1 (Gal-1) has been identified as a new PET imaging biomarker for immune checkpoint blockade (ICB) therapy, allowing physicians to predict the tumor responses before beginning treatment.

15 May 2024

Two studies aim to fight cancer with artificial cells

Fighting cancer with artificial cells that are capable of detecting and treating it. This is the dual objective of a research team of the Department of Cellular, Computational and Integrative Biology - Cibio of UniTrento, which has recently started two European projects funded by the Horizon Europe - EIC Pathfinder Open program.

6 May 2024